Literature DB >> 10744363

Pharmacodynamics of fluconazole, itraconazole, and amphotericin B against Candida albicans.

D S Burgess1, R W Hastings, K K Summers, T C Hardin, M G Rinaldi.   

Abstract

The objective of this study was to evaluate the pharmacodynamic activity of fluconazole, itraconazole, and amphotericin B against Candida albicans. Susceptibilities were determined according to the NCCLS guidelines (M27). Time-kill studies were performed using antifungal concentrations of 0.25-32 x MIC. Samples were withdrawn at predetermined timepoints, then plated using a spiral plater. Colony counts were determined after incubation at 35 degrees C for 24 h. The AUKC(0-48) was plotted against the concentration/MIC ratio. Candida isolates (95-2672, 96-15, and 95-2542) were classified as susceptible, susceptible-dose dependent, and resistant to fluconazole and itraconazole (MIC = 0.25 and 0.03 microg/mL, 32 and 0.5 microg/mL, 64 and 1 microg/mL; respectively). All three isolates were susceptible to amphotericin B (MIC = 0.13 microg/mL). Fluconazole inhibited the growth of the susceptible and S-DD isolates and was ineffective at all concentrations against the resistant isolate. Itraconazole, on the other hand, inhibited growth of the susceptible isolate, but was ineffective for the S-DD and resistant isolates. Maximal effectiveness was noted at the concentration 8 x MIC and 2 x MIC for fluconazole and itraconazole, respectively. Amphotericin B demonstrated concentration-dependent antifungal activity. The times necessary for the colony counts to fall below the limit of quantification were inversely related to increasing concentrations of amphotericin B. The maximal effect for amphotericin B was recorded at 2 x MIC. In summary, the triazoles inhibit growth of susceptible C. albicans; however, careful consideration should be given to the MIC for S-DD isolates because itraconazole may not be active if the MIC is reported in the higher susceptible-dose dependency range. In reference to amphotericin B, optimal activity may be achieved by maximizing the peak drug concentration/MIC ratio.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10744363     DOI: 10.1016/s0732-8893(99)00097-8

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  15 in total

Review 1.  Antifungal susceptibility testing: practical aspects and current challenges.

Authors:  J H Rex; M A Pfaller; T J Walsh; V Chaturvedi; A Espinel-Ingroff; M A Ghannoum; L L Gosey; F C Odds; M G Rinaldi; D J Sheehan; D W Warnock
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

Review 2.  Antifungal agents: in vitro susceptibility testing, pharmacodynamics, and prospects for combination therapy.

Authors:  A H Groll; H Kolve
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-03-11       Impact factor: 3.267

Review 3.  Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing.

Authors:  M A Pfaller; D J Diekema; D J Sheehan
Journal:  Clin Microbiol Rev       Date:  2006-04       Impact factor: 26.132

4.  Rationale for reading fluconazole MICs at 24 hours rather than 48 hours when testing Candida spp. by the CLSI M27-A2 standard method.

Authors:  Luis Ostrosky-Zeichner; John H Rex; Michael A Pfaller; Daniel J Diekema; Barbara D Alexander; David Andes; Steven D Brown; Vishnu Chaturvedi; Mahmoud A Ghannoum; Cindy C Knapp; Daniel J Sheehan; Thomas J Walsh
Journal:  Antimicrob Agents Chemother       Date:  2008-09-22       Impact factor: 5.191

Review 5.  Pharmacokinetic/pharmacodynamic profile of voriconazole.

Authors:  Ursula Theuretzbacher; Franziska Ihle; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 6.  Combination treatment of invasive fungal infections.

Authors:  Pranab K Mukherjee; Daniel J Sheehan; Christopher A Hitchcock; Mahmoud A Ghannoum
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

7.  In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies.

Authors:  Gordon Ramage; Kacy VandeWalle; Stefano P Bachmann; Brian L Wickes; José L López-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

8.  Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state.

Authors:  John E Conte; Jeffrey A Golden; Juliana Kipps; Marina McIver; Elisabeth Zurlinden
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

9.  Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-beta-cyclodextrin in infants, children, and adolescents.

Authors:  Susan M Abdel-Rahman; Richard F Jacobs; Joseph Massarella; Ralph E Kauffman; John S Bradley; Hui C Kimko; Gregory L Kearns; Kevin Shalayda; Christopher Curtin; Samuel D Maldonado; Jeffrey L Blumer
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

10.  Effects of antifungal agents in sap activity of Candida albicans isolates.

Authors:  Carolina Rodrigues Costa; Rosália Santos Amorim Jesuíno; Janine de Aquino Lemos; Orionalda de Fátima Lisboa Fernandes; Lúcia Kioko Hasimoto e Souza; Xisto Sena Passos; Maria do Rosário Rodrigues Silva
Journal:  Mycopathologia       Date:  2009-08-15       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.